CTOs on the Move

Princeton Separations Inc

www.prinsep.com

 
Princeton Separations Inc is a Freehold, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.prinsep.com
  • 100 Commerce Ave
    Freehold, NJ USA 07728
  • Phone: 732.431.3338

Executives

Name Title Contact Details

Similar Companies

Precept Life Sciences

Precept Life Sciences is a Reston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CoDa Therapeutics

CoDa Therapeutics is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cell Therapeutics

Cell Therapeutics, Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Coya Therapeutics

The company`s proprietary CTreg™ (cryopreservation for Tregs) system is the first in the industry to create an `off the shelf` approach to Treg cell therapy allowing for serial infusions. Through our patented TAI™ (Tregs Against Inflammation) and EAI™ (Exosomes Against Inflammation) platforms , Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Parkinson`s, Alzheimer`s, FTD and autoimmune diseases.

resTORbio

resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio`s lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions. Initially, resTORbio is focused on developing medicines that address conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio has initiated a Phase 2b trial for its lead product candidate, RTB101, evaluating its potential to reduce the incidence of respiratory tract infections (RTI) in elderly individuals at increased risk of RTI-related morbidity and mortality. resTORbio`s lead program is built upon two Phase 2a clinical studies demonstrating promising safety and efficacy results in almost 500 elderly individuals.